Dr. Bekaii-Saab on the Response Rate of Pembrolizumab in MSI-H CRC

Tanios Bekaii-Saab, MD
Published: Tuesday, Oct 31, 2017



Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the response rate of pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC).

According to Bekaii-Saab, when looking at the patient population that has this MSI-H phenotype, response rates are up to 50% to 60%. In recent publications that looked at pembrolizumab in patients with MSI-H, many of the patients who had either stable disease or a partial response (PR) ended up with complete response (CR).

However, it was an average of about 24 to 26 weeks before they had better responses. Some of these benefits can be seen earlier, but they also accumulate with time, explains Bekaii-Saab. Many of these patients end up with a CR or a very solid PR after 6 months on the therapy.
 


Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the response rate of pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC).

According to Bekaii-Saab, when looking at the patient population that has this MSI-H phenotype, response rates are up to 50% to 60%. In recent publications that looked at pembrolizumab in patients with MSI-H, many of the patients who had either stable disease or a partial response (PR) ended up with complete response (CR).

However, it was an average of about 24 to 26 weeks before they had better responses. Some of these benefits can be seen earlier, but they also accumulate with time, explains Bekaii-Saab. Many of these patients end up with a CR or a very solid PR after 6 months on the therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x